close

Boundless Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Business Officer, Neil Abdollahian, will present at the 22nd Annual Needham Healthcare Conference which will take place virtually. Presentation details are as follows:

Date: Tuesday, April 18, 2023

Time: 4:30 – 5:10 PM ET

About Boundless Bio

Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  261.73
-4.11 (-1.55%)
AAPL  317.00
+0.17 (0.05%)
AMD  464.25
-2.17 (-0.47%)
BAC  62.72
-0.45 (-0.72%)
GOOG  338.85
-2.85 (-0.83%)
META  542.47
-3.56 (-0.65%)
MSFT  482.39
-1.92 (-0.40%)
NVDA  216.55
-1.01 (-0.46%)
ORCL  141.51
-2.30 (-1.60%)
TSLA  342.96
-8.16 (-2.32%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at /week.